Compare VanEck Australian Floating Rate ETF (FLOT) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Gilead Sciences, Inc. — how do they compare? VanEck Australian Floating Rate ETF trades at $50.97, while Gilead Sciences, Inc. trades at $135.59 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while VanEck Australian Floating Rate ETF pays none, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| FLOT | GILD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $51.09 | $155.80 |
52-Week Low | $50.72 | $108.22 |
Market Cap | — | $163.51B |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT (iShares Floating Rate Bond ETF) trades at $50.97, showing minimal daily movement with a neutral technical signal. The ETF focuses on high-quality floating rate bonds with a 4.0% SEC yield, positioning it as a defensive holding amid rising rate expectations. Recent dividends of $0.17-$0.18 reflect steady income generation, while technical indicators show mixed signals with bullish moving averages but bearish ADX readings.
The outlook remains stable with potential upside if the Federal Reserve implements rate hikes later in 2026, which would boost FLOT's yield. However, the ETF faces headwinds from inflation pressures and geopolitical tensions affecting Treasury yields. Current neutral sentiment suggests FLOT serves as a cash parking vehicle rather than a growth investment, with limited price appreciation potential but reliable income generation.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
